PBI20 SECUKINUMAB VS. ADALIMUMAB AND INFLIXIMAB FOR THE TREATMENT OF ANKYLOSING SPONDYLITIS: A COST PER RESPONDER ANALYSIS AT 52 WEEKS FROM A GREEK PERSPECTIVE
Nov 1, 2019, 00:00 AM
10.1016/j.jval.2019.09.124
https://www.valueinhealthjournal.com/article/S1098-3015(19)32502-1/fulltext
Section Title :
Section Order :
10081
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(19)32502-1&doi=10.1016/j.jval.2019.09.124